Translational Glycobiology in Human Health and Disease
- 1st Edition - November 29, 2023
- Editors: Michelle Kilcoyne, Lokesh Joshi
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 9 6 5 5 - 7
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 0 0 2 - 3
Along with nucleic acids, proteins, and lipids, carbohydrates stand as one of four main components of cellular architecture. However, glycobiology (or carbohydrate bioscience) is… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAlong with nucleic acids, proteins, and lipids, carbohydrates stand as one of four main components of cellular architecture. However, glycobiology (or carbohydrate bioscience) is little understood by non-experts, partly because carbohydrates are a complex, diverse class of molecules structurally and functionally. In recent years, advances in computational analytics (glycomics) have allowed us to better interpret and realize the importance of glycobiology in human health and disease, and glycans and their associated processes have been shown to play a significant role across a variety of disease types. As the biomedical sciences continue to adopt multi-omic and precision medicine approaches, a greater understanding of glycobiology is essential for maintaining healthy physiology and advancing disease treatment.
Translational Glycobiology in Human Health and Disease offers a deep examination of glycobiology for experts and non-experts alike in areas ranging from the role of glycobiology in chronic and infectious diseases to advances in technologies for higher throughput analysis and diagnosis. While keeping human health in the forefront, this book integrates a thorough discussion of glycobiology fundamentals with its growing areas of application and societal impact. With emphasis throughout on the interdisciplinary nature of glycosciences, this book also features perspectives from the health, computational (glycoanalytics), materials, biopharmaceutical, and diagnostic sciences.
Disease and speciality areas addressed include gycoimmunology, neuroglycobiology, commensal glycobiology, gut health, regenerative medicine and glycobiology, glycobiology and cancer, congenital disorders of glycosylation, infectious disease glycobiology, and parasite glycobiology. Computational approaches discussed, supporting the advance of new research, include advanced glycoanalytics, glycomics microarrays, glycoengineering, and glycol systems biology. Additionally, authors consider impact areas for society and public health, such as glycobiology and entrepreneurship, policy and regulatory requirements for glycosylation, future research, and translation to new diagnostics and drug discovery.
Translational Glycobiology in Human Health and Disease offers a deep examination of glycobiology for experts and non-experts alike in areas ranging from the role of glycobiology in chronic and infectious diseases to advances in technologies for higher throughput analysis and diagnosis. While keeping human health in the forefront, this book integrates a thorough discussion of glycobiology fundamentals with its growing areas of application and societal impact. With emphasis throughout on the interdisciplinary nature of glycosciences, this book also features perspectives from the health, computational (glycoanalytics), materials, biopharmaceutical, and diagnostic sciences.
Disease and speciality areas addressed include gycoimmunology, neuroglycobiology, commensal glycobiology, gut health, regenerative medicine and glycobiology, glycobiology and cancer, congenital disorders of glycosylation, infectious disease glycobiology, and parasite glycobiology. Computational approaches discussed, supporting the advance of new research, include advanced glycoanalytics, glycomics microarrays, glycoengineering, and glycol systems biology. Additionally, authors consider impact areas for society and public health, such as glycobiology and entrepreneurship, policy and regulatory requirements for glycosylation, future research, and translation to new diagnostics and drug discovery.
- Provides a deep, foundational overview of glycoscience and its translational potential, highlighting glycobiology’s growing role in human health and disease study
- Examines a broad range of relevant disease areas and applications of glycobiology in policy and public health
- Features chapter contributions from leading, international experts in the field, fully integrating perspectives from the health, computational, materials, biopharmaceutical, and diagnostic sciences
Active researchers in biochemistry, molecular biology, nutrition, and cell biology, industrial scientists, biomedical engineers, nutritional scientists, pharmacologists, clinician scientists, medicinal chemists, analytical chemists
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Introduction
- Section 1. Glycobiology
- Chapter 1. Carbohydrates and human glycosylation
- 1.1. Introduction
- 1.2. Glycoconjugate structures
- 1.3. Nonhuman carbohydrates
- 1.4. Recycling of monosaccharides
- 1.5. Glycosylation and the exracellular matrix
- 1.6. Conclusion
- Chapter 2. Lectins and their applications in biomedical research
- 2.1. Introduction
- 2.2. Plant lectins
- 2.3. Applications of lectins in biomedical research
- 2.4. Conclusions
- Chapter 3. Carbohydrate-active enzymes
- 3.1. Introduction
- 3.2. Glycosyltransferases
- 3.3. Glycosidases
- Chapter 4. Carbohydrate sulfotransferases in glycosaminoglycan biosynthesis
- 4.1. Introduction
- 4.2. Two carbohydrate sulfotransferases superfamilies
- 4.3. Glycosaminoglycan sulfotransferases
- 4.4. Biomedical applications of sulfated glycosaminoglycans
- Section 2. Glycobiology and health
- Chapter 5. The immune system from a glycobiological point of view
- 5.1. The immune system beyond pathogens: dissecting dangerous self and nonself signals
- 5.2. The sweet side of the immune system
- 5.3. Cellular immunity
- 5.4. Adaptive immune response: B cells from a glycobiological perspective
- 5.5. Complement: the soluble component of innate immunity
- 5.6. Conclusions
- Chapter 6. Host mucin glycosylation and gut symbiosis
- 6.1. Introduction
- 6.2. Mucin glycosylation along the GI tract
- 6.3. Role of mucin glycosylation in symbiosis: a bidirectional relationship
- 6.4. Mucin glycan utilization strategies by gut bacteria
- 6.5. Implication of mucin glycosylation in dysbiosis-mediated diseases
- 6.6. Future directions
- Chapter 7. Bifidobacteria-accessible carbohydrates in milk
- 7.1. Introduction
- 7.2. General features of bifidobacteria HMO metabolism
- 7.3. Milk glycoconjugate metabolism
- 7.4. Conclusions
- Chapter 8. Extracellular vesicle glycosylation in transport, signaling, and function
- 8.1. A short introduction to extracellular vesicles
- 8.2. The beginning of the EV gold rush
- 8.3. The challenges of EV glycobiological analysis
- 8.4. Human EV glycome
- 8.5. Glycans in EV function
- 8.6. In closing, EV glycosylation and future prospects
- Section 3. Glycobiology and disease
- Chapter 9. Protein glycosylation in cancer
- 9.1. Introduction
- 9.2. Hexosamine biosynthetic pathway and cancer
- 9.3. O-GlcNAcylation and cancer
- 9.4. N-glycosylation in cancer
- 9.5. O-linked N-acetylgalactosamine in cancer
- 9.6. N- and O-linked glycan capping in cancer
- 9.7. Sialic acid in tumor biology
- 9.8. Proteoglycans and glycosaminoglycans in cancer
- 9.9. Conclusions
- Chapter 10. Metabolic diseases: disorders of carbohydrate metabolism and lysosomal storage
- 10.1. Introduction
- 10.2. Disorders of carbohydrate metabolism
- 10.3. Lysosomal storage diseases
- Chapter 11. The glycobiology of microbial infectious disease
- 11.1. Introduction
- 11.2. Carbohydrate-involved virulence factors
- 11.3. Current carbohydrate-based antimicrobial therapeutics and prophylactics
- 11.4. Current research and development for carbohydrate-based antimicrobial strategies
- 11.5. Conclusions
- Section 4. Glycotechnologies
- Chapter 12. Elucidation of the structure of carbohydrates and their interactions by nuclear magnetic resonance spectroscopy
- 12.1. Introduction
- 12.2. Assignment of carbohydrate resonances
- 12.3. Study of carbohydrate conformations
- 12.4. NMR tools for analyzing the interplay between carbohydrates and proteins
- Chapter 13. Development of glycosensors and their applications
- 13.1. Introduction
- 13.2. Diverse approaches to recognize glycosylation
- 13.3. Modern analytical technologies applied in glycosensors
- 13.4. Applications of glycosensors in disease monitoring, diagnostics, and treatment
- 13.5. Conclusion
- Chapter 14. Systems glycoengineering of therapeutic proteins
- 14.1. Introduction
- 14.2. Market and impact of glycoengineering on clinical success
- 14.3. Glycoforms relevant to therapeutic proteins
- 14.4. Impact of combined glycoengineering inputs on therapeutic proteins
- 14.5. Applying systems glycoengineering to biomanufacturing
- 14.6. Systems-level “omics” glycoengineering
- 14.7. Glycoinformatics and bioinformatics
- 14.8. Summary and conclusions
- Chapter 15. Understanding glycobiology through multiscale molecular dynamics simulations: From basic principles to case studies
- 15.1. Introduction
- 15.2. Computational background
- 15.3. Applications of multiscale MD simulations in glycobiology
- 15.4. Conclusions
- Section 5. Glycobiology and society
- Chapter 16. Improving impact: Public involvement in glycobiology research
- 16.1. Responsible research and innovation
- 16.2. Terminology for public engagement in research
- 16.3. Public involvement in research
- 16.4. I work in a lab, why should the public be involved in my research?
- 16.5. Evidence for public involvement in research
- 16.6. Involvement throughout the research cycle
- 16.7. Where to engage the public
- 16.8. Summary
- Chapter 17. Public health and translational glycobiology
- 17.1. Introduction: a concise primer on Glycans
- 17.2. How glycans influence blood transfusions
- 17.3. How glycans influence microbial infections and interactions
- 17.4. How glycans influence diabetes and obesity
- 17.5. How glycans contribute to congenital disorders
- 17.6. Closing thoughts
- Index
- No. of pages: 480
- Language: English
- Edition: 1
- Published: November 29, 2023
- Imprint: Academic Press
- Paperback ISBN: 9780128196557
- eBook ISBN: 9780128220023
MK
Michelle Kilcoyne
Dr. Michelle Kilcoyne is Lecturer in Glycosciences at the National University of Ireland Galway. Dr. Michelle Kilcoyne completed her PhD in analytical carbohydrate chemistry in the School of Chemistry at NUI Galway in 2004, specialising in structural analysis of bacterial polysaccharides. She then took up a postdoctoral position in Arizona State University where she further specialised in mass spectrometry and HPLC, as well as expanding her interests to mammalian glycosylation. She returned as a postdoctoral researcher to NUI Galway in 2007 working on industry-supported and European projects, developing high throughput platforms for carbohydrate profiling. In 2014 Dr. Kilcoyne was appointed Lecturer in Glycosciences, is currently a member of Discipline of Microbiology at NUI Galway and leads the Carbohydrate Signalling Group. She is the recipient of a Royal Society of Chemistry Analytical Chemistry Trust Fund Fellowship for 2018. Her main interests are in glycoanalytics, novel glycomics platform development and carbohydrate-mediated host-microbe interactions.
Affiliations and expertise
Lecturer in Glycosciences, National University of Ireland, Galway, IrelandLJ
Lokesh Joshi
Prof. Lokesh Joshi is Director of the Advanced Glycoscience Research Cluster and leader of the Glycoscience Group at NUI Galway, a Co-Director of CÚRAM, a medical device centre, and the Vice-President for Research at NUI Galway. His principal focus of research is in understanding the roles of glycans and lectins in health and diseases and developing novel technologies for glycomics. Prof. Joshi has been involved in two spin out companies, Arizona Engineered Therapeutics (AzERx) and Aquila Biosciences. The NIH and VC sources funded AzERx to develop peptide-based therapeutics for vascular applications and AzERx was acquired by Orthologic (Now Capstone Therapeutics) in 2006. Aquila Bioscience is a healthcare company working on various projects funded by EI, EU, European Defence Agency and private industries. Prof. Joshi is an SFI-Stokes Professor of Glycosciences and the Irish representative on European Universities Association’s Research Programme Working group.
Affiliations and expertise
Director, Advanced Glycoscience Research Cluster and Leader, Glycoscience Group, NUI Galway, IrelandRead Translational Glycobiology in Human Health and Disease on ScienceDirect